With a year's worth of progress on the would-be competition targeting cholesterol by way of a new mechanism, Regeneron Pharmaceuticals Inc. and partner Sanofi SA set forth on another Phase III trial – this time measuring cardiovascular (CV) outcomes – with SAR236553/REGN727.